Matrix Metalloproteinases in Inflammatory Bowel Disease: An Update
暂无分享,去创建一个
[1] D. Shaw,et al. Angiogenesis blockade as a new therapeutic approach to experimental colitis , 2006, Gut.
[2] F. Paolicchi,et al. Mycobacterium avium subsp. paratuberculosis: presencia en los alimentos y su relación con la enfermedad de Crohn , 2007 .
[3] J. Fletcher,et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) Study Identifies Fecal Calprotectin, Serum MMP9, and Serum IL-22 as a Novel Combination of Biomarkers for Crohn's Disease Activity: Role of Cross-Sectional Imaging , 2013, The American Journal of Gastroenterology.
[4] M. Cola,et al. Inhibitor of PI3Kγ ameliorates TNBS‐induced colitis in mice by affecting the functional activity of CD4+CD25+FoxP3+ regulatory T cells , 2011, British journal of pharmacology.
[5] Judy H. Cho,et al. A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.
[6] E. Roeb,et al. Presence of intestinal Mycobacterium avium subspecies paratuberculosis (MAP) DNA is not associated with altered MMP expression in ulcerative colitis , 2011, BMC gastroenterology.
[7] M. Lukáš. Inflammatory Bowel Disease as a Risk Factor for Colorectal Cancer , 2010, Digestive Diseases.
[8] M. Federici,et al. Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine. , 2012, Gastroenterology.
[9] A. Kraneveld,et al. Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease , 2013, Gut.
[10] D. Podolsky. The current future understanding of inflammatory bowel disease. , 2002, Best practice & research. Clinical gastroenterology.
[11] S. Wenzel,et al. Mechanisms of tissue inhibitor of metalloproteinase 1 augmentation by IL-13 on TGF-beta 1-stimulated primary human fibroblasts. , 2007, The Journal of allergy and clinical immunology.
[12] Marloes A. A. Schepens,et al. Supplemental calcium attenuates the colitis-related increase in diarrhea, intestinal permeability, and extracellular matrix breakdown in HLA-B27 transgenic rats. , 2009, The Journal of nutrition.
[13] A. Sabatino,et al. Role of Macrophage Metalloelastase in Gut Inflammation , 2006, Annals of the New York Academy of Sciences.
[14] K. Hahm,et al. Prevention of Colitis-Associated Carcinogenesis with Infliximab , 2010, Cancer Prevention Research.
[15] P. Garg,et al. Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. , 2009, American journal of physiology. Gastrointestinal and liver physiology.
[16] E. Mazzon,et al. Matrix metalloproteinase‐9 and metalloproteinase‐2 activity and expression is reduced by melatonin during experimental colitis , 2008, Journal of pineal research.
[17] K. Rhee,et al. Matrilysin‐1 (MMP7) cleaves galectin‐3 and inhibits wound healing in intestinal epithelial cells , 2011, Inflammatory bowel diseases.
[18] J. Fletcher,et al. Erratum: EMerging BiomARKers in inflammatory bowel disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for crohn's disease activity: Role of cross-sectional imaging (American Journal of Gastroenterology (2013) 108 (1891-1900) DOI: 10 , 2014 .
[19] A. Catto-Smith,et al. Expression profile of genes involved in pathogenesis of pediatric Crohn's disease , 2012, Journal of gastroenterology and hepatology.
[20] Judy H. Cho,et al. [Letters to Nature] , 1975, Nature.
[21] G. Bancroft,et al. Production of Matrix Metalloproteinases in Response to Mycobacterial Infection , 2001, Infection and Immunity.
[22] M. Comalada,et al. The association of minocycline and the probiotic Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS model of reactivated colitis in mice. , 2011, Biochemical pharmacology.
[23] M. Washington,et al. Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling , 2013, Gut.
[24] Jialiang Hu,et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases , 2007, Nature Reviews Drug Discovery.
[25] J. Satsangi,et al. A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. , 2001, Gastroenterology.
[26] T. Kirkegaard,et al. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium , 2009, Clinical and experimental immunology.
[27] S. Chi,et al. Oral administration of docosahexaenoic acid attenuates colitis induced by dextran sulfate sodium in mice. , 2011, Molecular nutrition & food research.
[28] T. Macdonald,et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21 , 2006, Gut.
[29] Peasad Devarajan. Neutrophil gelatinase‐associated lipocalin (NGAL): A new marker of kidney disease , 2008, Scandinavian journal of clinical and laboratory investigation. Supplementum.
[30] A. Morgan,et al. Genetic variations in matrix metalloproteinases may be associated with increased risk of ulcerative colitis. , 2011, Human immunology.
[31] K. Shirouzu,et al. Increased claudin-1 protein expression contributes to tumorigenesis in ulcerative colitis-associated colorectal cancer. , 2010, Anticancer research.
[32] H. Steinhart,et al. IBD Around the world: Comparing the epidemiology, diagnosis, and treatment: Proceedings of the World Digestive Health Day 2010 ‐ Inflammatory bowel disease task force meeting , 2011, Inflammatory bowel diseases.
[33] Carlos López-Otín,et al. Strategies for MMP inhibition in cancer: innovations for the post-trial era , 2002, Nature Reviews Cancer.
[34] J. Terwilliger,et al. Two stage genome–wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12 , 1996, Nature Genetics.
[35] Judy H. Cho,et al. The Nod2 Gene in Crohn's Disease: Implications for Future Research Into the Genetics and Immunology of Crohn's Disease , 2001, Inflammatory bowel diseases.
[36] C. López-Otín,et al. Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF , 2013, EMBO molecular medicine.
[37] S. Sanyal,et al. The PI3K/Akt pathway in colitis associated colon cancer and its chemoprevention with celecoxib, a Cox-2 selective inhibitor. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[38] Jing-Wei Mao,et al. Expression of matrix metalloproteinase-1 and tumor necrosis factor-α in ulcerative colitis , 2007 .
[39] Steven C Ricke,et al. Current perspectives on Mycobacterium avium subsp. paratuberculosis, Johne’s disease, and Crohn’s disease: a Review , 2011, Critical reviews in microbiology.
[40] P. E. Van den Steen,et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade , 2013, Critical reviews in biochemistry and molecular biology.
[41] G. Jena,et al. Role of α-lipoic acid in dextran sulfate sodium-induced ulcerative colitis in mice: studies on inflammation, oxidative stress, DNA damage and fibrosis. , 2013, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[42] T. Ayabe,et al. Bactericidal Activity of Mouse α-Defensin Cryptdin-4 Predominantly Affects Noncommensal Bacteria , 2010, Journal of Innate Immunity.
[43] Didier Merlin,et al. Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. , 2010, Cancer research.
[44] C. Overall,et al. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. , 2010, Biochimica et biophysica acta.
[45] E. Quintero,et al. Increased Activity and Expression of Gelatinases in Ischemic Colitis , 2006, Digestive Diseases and Sciences.
[46] X. Tan,et al. Correlation of Plasma MMP-1 and TIMP-1 Levels and the Colonic Mucosa Expressions in Patients with Ulcerative Colitis , 2009, Mediators of inflammation.
[47] B. Fingleton,et al. Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.
[48] G. Kolios,et al. Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. , 2013, Journal of Crohn's & colitis.
[49] S. Rose-John,et al. TNFα cleavage beyond TACE/ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis , 2013, EMBO molecular medicine.
[50] Federico Díaz-González,et al. Up-regulation of gelatinases in the colorectal adenoma-carcinoma sequence. , 2006, European journal of cancer.
[51] B. Zilberstein,et al. Bacterial translocation: Overview of mechanisms and clinical impact , 2007, Journal of gastroenterology and hepatology.
[52] D. Zurakowski,et al. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease , 2008, Inflammatory bowel diseases.
[53] S. García-Mauriño,et al. Melatonin, autophagy and intestinal bowel disease. , 2014, Current pharmaceutical design.
[54] A. Sabatino,et al. CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.
[55] K. Kolho,et al. Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values , 2009, International Journal of Colorectal Disease.
[56] A. Franke,et al. Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[57] A. Steinmeyer,et al. The New Low Calcemic Vitamin D Analog 22-Ene-25-Oxa-Vitamin D Prominently Ameliorates T Helper Cell Type 1-Mediated Colitis in Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.
[58] M. Milla,et al. Down-regulation of adhesion molecules and matrix metalloproteinases by ZK 156979 in inflammatory bowel diseases. , 2010, Clinical immunology.
[59] Jing-Wei Mao,et al. Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats. , 2012, World journal of gastroenterology.
[60] T. Sørensen,et al. Familial occurrence of inflammatory bowel disease. , 1991, The New England journal of medicine.
[61] P. Billings,et al. Activation of Transforming Growth Factor β in Chondrocytes Undergoing Endochondral Ossification , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[62] S. Doan,et al. EMMPRIN modulates epithelial barrier function through a MMP-mediated occludin cleavage: implications in dry eye disease. , 2011, The American journal of pathology.
[63] D. Bernardo,et al. High Levels of Proinflammatory Cytokines, but Not Markers of Tissue Injury, in Unaffected Intestinal Areas from Patients with IBD , 2009, Mediators of inflammation.
[64] M. Khaitsa,et al. Epidemiological evidence for Mycobacterium avium subspecies paratuberculosis as a cause of Crohn's disease , 2007, Epidemiology and Infection.
[65] P. Hellström,et al. Nitric oxide pathway-related gene alterations in inflammatory bowel disease , 2012, Scandinavian journal of gastroenterology.
[66] M. Sefton,et al. Effect of a matrix metalloproteinase sequestering biomaterial on Caco-2 epithelial cell barrier integrity in vitro. , 2009, Acta biomaterialia.
[67] A. Andicoechea,et al. Collagenase-3 (MMP-13) expression by inflamed mucosa in inflammatory bowel disease , 2006, Scandinavian journal of gastroenterology.
[68] X. Tan,et al. Effect of Etiasa on the expression of matrix metalloproteinase-2 and tumor necrosis factor-α in a rat model of ulcerative colitis. , 2012, Molecular medicine reports.
[69] O. Nielsen,et al. Inflammatory pathways of importance for management of inflammatory bowel disease. , 2014, World journal of gastroenterology.
[70] E S Lander,et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. , 2000, American journal of human genetics.
[71] P. Coussens,et al. Johne's disease in cattle is associated with enhanced expression of genes encoding IL-5, GATA-3, tissue inhibitors of matrix metalloproteinases 1 and 2, and factors promoting apoptosis in peripheral blood mononuclear cells. , 2005, Veterinary immunology and immunopathology.
[72] Jean Weissenbach,et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16 , 1996, Nature.
[73] P. Rutgeerts,et al. Infliximab Restores the Dysfunctional Matrix Remodeling Protein and Growth Factor Gene Expression in Patients with Inflammatory Bowel Disease , 2014, Inflammatory bowel diseases.
[74] R. Cortivo,et al. Effects of Th2 cytokines on expression of collagen, MMP-1, and TIMP-1 in conjunctival fibroblasts. , 2003, Investigative ophthalmology & visual science.
[75] G. Jena,et al. Melatonin Reduces Ulcerative Colitis-Associated Local and Systemic Damage in Mice: Investigation on Possible Mechanisms , 2013, Digestive Diseases and Sciences.
[76] M. Radomski,et al. Role of Matrix Metalloproteinases in Intestinal Inflammation , 2006, Journal of Pharmacology and Experimental Therapeutics.
[77] S. Takai,et al. Role of Chymase-Dependent Matrix Metalloproteinase-9 Activation in Mice with Dextran Sodium Sulfate-Induced Colitis , 2008, Journal of Pharmacology and Experimental Therapeutics.
[78] J. González‐Gallego,et al. Glutamine prevents fibrosis development in rats with colitis induced by 2,4,6-trinitrobenzene sulfonic acid. , 2010, The Journal of nutrition.
[79] E. Mazzon,et al. Melatonin reduces dinitrobenzene sulfonic acid‐induced colitis , 2001, Journal of pineal research.
[80] C. Haglund,et al. Low trypsinogen-1 expression in pediatric ulcerative colitis patients who undergo surgery. , 2013, World journal of gastroenterology.
[81] A. Ouellette,et al. Matrix Metalloproteinase-7 Activation of Mouse Paneth Cell Pro-α-defensins , 2006, Journal of Biological Chemistry.
[82] John M. Whitelock,et al. The Degradation of Human Endothelial Cell-derived Perlecan and Release of Bound Basic Fibroblast Growth Factor by Stromelysin, Collagenase, Plasmin, and Heparanases (*) , 1996, The Journal of Biological Chemistry.
[83] A. Kostic,et al. The microbiome in inflammatory bowel disease: current status and the future ahead. , 2014, Gastroenterology.
[84] P. Rutgeerts,et al. Neutrophil Gelatinase B–associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Serum Marker of Mucosal Healing in Ulcerative Colitis , 2014, Inflammatory bowel diseases.
[85] J. Clancy,et al. A Novel Proteolytic Cascade Generates an Extracellular Matrix-Derived Chemoattractant in Chronic Neutrophilic Inflammation12 , 2008, The Journal of Immunology.
[86] A. Gamian,et al. Matrix Metalloproteinase-9: Its Interplay with Angiogenic Factors in Inflammatory Bowel Diseases , 2014, Disease markers.
[87] J. Elguero,et al. Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases. , 2009, Bioorganic & medicinal chemistry.
[88] S. Targan,et al. Linkage of Crohn’s disease to the major histocompatibility complex region is detected by multiple non-parametric analyses , 1999, Gut.
[89] B. Fingleton,et al. Lack of MMP10 exacerbates experimental colitis and promotes development of inflammation-associated colonic dysplasia , 2012, Laboratory Investigation.
[90] A. Keshavarzian,et al. The role of matrix metalloproteinases in intestinal epithelial wound healing during normal and inflammatory states. , 2011, The Journal of surgical research.
[91] Z. Werb,et al. New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.
[92] J. Epstein,et al. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1β and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease , 2009, British Journal of Nutrition.
[93] N. Mukaida,et al. Crucial Involvement of Tumor-Associated Neutrophils in the Regulation of Chronic Colitis-Associated Carcinogenesis in Mice , 2012, PloS one.
[94] C. Dietrich,et al. Enhanced expression of MMP‐7 and MMP‐13 in inflammatory bowel disease: A precancerous potential? , 2006, Inflammatory bowel diseases.
[95] Y. Naito,et al. Early-stage blocking of Notch signaling inhibits the depletion of goblet cells in dextran sodium sulfate-induced colitis in mice , 2010, Journal of Gastroenterology.
[96] Y. Chao,et al. Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. , 2009, Toxicology and applied pharmacology.
[97] Z. Werb,et al. How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.
[98] J. Bartlett,et al. The role of the intestinal microflora in experimental colitis. , 1977, The American journal of clinical nutrition.
[99] C. López-Otín,et al. Matrix Metalloprotease 8-Dependent Extracellular Matrix Cleavage at the Blood–CSF Barrier Contributes to Lethality during Systemic Inflammatory Diseases , 2012, The Journal of Neuroscience.
[100] M. Egger,et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. , 2007, The Lancet. Infectious diseases.
[101] E. Mazzon,et al. Teupolioside, a phenylpropanoid glycosides of Ajuga reptans, biotechnologically produced by IRBN22 plant cell line, exerts beneficial effects on a rodent model of colitis. , 2009, Biochemical pharmacology.
[102] J. Schölmerich,et al. Calcitriol analog ZK191784 ameliorates acute and chronic dextran sodium sulfate-induced colitis by modulation of intestinal dendritic cell numbers and phenotype. , 2007, World journal of gastroenterology.
[103] Z. Tulassay,et al. The Impact of Matrix Metalloproteinases and Their Tissue Inhibitors in Inflammatory Bowel Diseases , 2012, Digestive Diseases.
[104] Subrata Ghosh,et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.
[105] Shigeyoshi Itohara,et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.
[106] S. Hanauer,et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. , 1991, Gut.
[107] H. Verspaget,et al. Effect of the anti‐tumor necrosis factor‐&agr; antibody infliximab on the ex vivo mucosal matrix metalloproteinase–proteolytic phenotype in inflammatory bowel disease , 2007, Inflammatory bowel diseases.
[108] M. Sinnamon,et al. Essential role for mast cell tryptase in acute experimental colitis , 2010, Proceedings of the National Academy of Sciences.
[109] F. Carbonnel,et al. Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.
[110] C. J. Taylor,et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. , 1999, Gastroenterology.
[111] N. Docherty,et al. Fibrogenesis in Crohn's Disease , 2007, The American Journal of Gastroenterology.
[112] B. Iwańczak,et al. Metalloproteinase-3 and -9 as novel markers in the evaluation of ulcerative colitis activity in children. , 2014, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[113] J. Kang,et al. Cox-2 expression, PGE(2) and cytokines production are inhibited by endogenously synthesized n-3 PUFAs in inflamed colon of fat-1 mice. , 2011, The Journal of nutritional biochemistry.
[114] Wei Wang,et al. Protective effect of ilomastat on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. , 2008, World journal of gastroenterology.
[115] T. Karlsen,et al. Update on primary sclerosing cholangitis. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[116] M. Lipko,et al. Colonic gene expression profile in NHE3-deficient mice: evidence for spontaneous distal colitis. , 2008, American journal of physiology. Gastrointestinal and liver physiology.
[117] S. Dedhar,et al. Integrin-linked kinase regulates cell proliferation and tumour growth in murine colitis-associated carcinogenesis , 2008, Gut.
[118] Jack Satsangi,et al. Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis , 2008, Gut.
[119] D. Nguyen,et al. Animal models of ulcerative colitis and their application in drug research , 2013, Drug design, development and therapy.
[120] E. Roeb,et al. Induction of matrix metalloproteinases and TLR2 and 6 in murine colon after oral exposure to Mycobacterium avium subsp. paratuberculosis. , 2012, Microbes and infection.
[121] K. Kolho,et al. Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease , 2010, Scandinavian journal of gastroenterology.
[122] N. Wright,et al. Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut. , 2007, Pharmacology & therapeutics.
[123] E. Goetzl,et al. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis. , 2011, Cellular immunology.
[124] E. Mazzon,et al. Effects of verbascoside biotechnologically produced by Syringa vulgaris plant cell cultures in a rodent model of colitis , 2009, Naunyn-Schmiedeberg's Archives of Pharmacology.
[125] Mourad Sahbatou,et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.
[126] S. Szabó,et al. Mesalamine Restores Angiogenic Balance in Experimental Ulcerative Colitis by Reducing Expression of Endostatin and Angiostatin: Novel Molecular Mechanism for Therapeutic Action of Mesalamine , 2009, Journal of Pharmacology and Experimental Therapeutics.
[127] C. Loddenkemper,et al. Selective gelatinase blockage ameliorates acute DSS colitis. , 2011, European journal of microbiology & immunology.
[128] M. Parkes,et al. Evidence for inflammatory bowel disease of a susceptibility locus on the X chromosome. , 2001, Gastroenterology.
[129] G. Corazza,et al. Transforming growth factor β signalling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures , 2009, Gut.
[130] K. Boberg,et al. Association of matrix metalloproteinase-1 and -3 promoter polymorphisms with clinical subsets of Norwegian primary sclerosing cholangitis patients. , 2004, Journal of hepatology.
[131] M. Silverberg,et al. Gene Expression Changes Associated with Resistance to Intravenous Corticosteroid Therapy in Children with Severe Ulcerative Colitis , 2010, PloS one.
[132] K. Asadullah,et al. A novel immunosuppressive 1alpha,25-dihydroxyvitamin D3 analog with reduced hypercalcemic activity. , 2002, The Journal of investigative dermatology.
[133] 石田 久美. Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis , 2008 .
[134] Hye-Jin Park,et al. Ethanol Extract of Cordyceps militaris Grown on Germinated Soybeans Attenuates Dextran-Sodium-Sulfate- (DSS-) Induced Colitis by Suppressing the Expression of Matrix Metalloproteinases and Inflammatory Mediators , 2013, BioMed research international.
[135] J. Roman,et al. Matrix metalloproteinase-9 regulates MUC-2 expression through its effect on goblet cell differentiation. , 2007, Gastroenterology.
[136] A. Mazar,et al. Differential angiogenic regulation of experimental colitis. , 2006, The American journal of pathology.
[137] H. Verspaget,et al. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)‐2 and ‐9 in Crohn's disease , 2007, Inflammatory bowel diseases.
[138] E. Roeb,et al. Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis , 2010, Scandinavian journal of gastroenterology.
[139] H. Weinans,et al. The novel vitamin D analog ZK191784 as an intestine‐ specific vitamin D antagonist , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[140] M. Scott,et al. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. , 2009, Gastroenterology.
[141] M. Milla,et al. Role of vitamin D derivatives in intestinal tissue of patients with inflammatory bowel diseases. , 2014, Journal of Crohn's & colitis.
[142] K. Farkas,et al. Fecal MMP-9: A New Noninvasive Differential Diagnostic and Activity Marker in Ulcerative Colitis , 2013, Inflammatory bowel diseases.
[143] M. Radomski,et al. Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance--NO and MMP-9 interactions. , 2014, Biochimica et biophysica acta.
[144] R. Greenstein. Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. , 2003, The Lancet. Infectious diseases.
[145] W. Parks,et al. Matrix metalloproteinase‐7 (matrilysin) controls neutrophil egress by generating chemokine gradients , 2008, Journal of leukocyte biology.
[146] B. Molnár,et al. The Behavior of Matrix Metalloproteinase-9 in Lymphocytic Colitis, Collagenous Colitis and Ulcerative Colitis , 2011, Pathology & Oncology Research.
[147] E. Rozengurt,et al. Protein kinase D1 mediates synergistic MMP-3 expression induced by TNF-α and bradykinin in human colonic myofibroblasts. , 2011, Biochemical and biophysical research communications.
[148] C. Elson,et al. A Novel Role for Defensins in Intestinal Homeostasis: Regulation of IL-1β Secretion1 , 2007, The Journal of Immunology.
[149] L. Liotta,et al. Basement membrane collagen: degradation by migrating endothelial cells. , 1983, Science.
[150] I. Stamenkovic,et al. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.
[151] S. Itzkowitz,et al. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. , 2004, American journal of physiology. Gastrointestinal and liver physiology.
[152] J. Tajti,et al. The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases. , 2014, Journal of Crohn's & colitis.
[153] D. Hommes,et al. Role of matrix metalloproteinase,tissue inhibitor of metalloproteinase and tumor necrosis factor-α single nucleotide gene polymorphisms in inflammatory bowel disease , 2007 .
[154] Kwang Yeon Kim,et al. Familial occurrence of inflammatory bowel disease in Korea , 2006, Inflammatory bowel diseases.
[155] M. Luisa Iruela-Arispe,et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors , 2005, The Journal of cell biology.
[156] T. Salo,et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. , 2005, Experimental cell research.
[157] C. Probert,et al. IL-13 Promotes Collagen Accumulation in Crohn’s Disease Fibrosis by Down-Regulation of Fibroblast MMP Synthesis: A Role for Innate Lymphoid Cells? , 2012, PloS one.
[158] A. M. Houghton,et al. Macrophage elastase kills bacteria within murine macrophages , 2009, Nature.
[159] R. Hershberg,et al. Helicobacter-induced inflammatory bowel disease in IL-10- and T cell-deficient mice. , 2001, American journal of physiology. Gastrointestinal and liver physiology.
[160] J. Mendoza,et al. Mycobacterium avium subspecies paratuberculosis and its relationship with Crohn's disease. , 2009, World journal of gastroenterology.
[161] Judy H. Cho,et al. Refined genomic localization and ethnic differences observed for the IBD5 association with Crohn's disease , 2007, European Journal of Human Genetics.
[162] D. Sohn,et al. 2′,4′,6′-Tris(methoxymethoxy) chalcone protects against trinitrobenzene sulfonic acid-induced colitis and blocks tumor necrosis factor-α-induced intestinal epithelial inflammation via heme oxygenase 1-dependent and independent pathways , 2007 .
[163] P. Brigidi,et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial , 2003 .
[164] M. Stolte,et al. Allelic variation of the matrix metalloproteinase‐9 gene is associated with collagenous colitis , 2011, Inflammatory bowel diseases.
[165] L. Melton,et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. , 2006, Gastroenterology.
[166] M. Radomski,et al. Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion. , 2012, Journal of medicinal chemistry.
[167] M. Gareau,et al. Matrix metalloproteinase 9 contributes to gut microbe homeostasis in a model of infectious colitis , 2012, BMC Microbiology.
[168] G. Rogler,et al. Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. , 2014, Journal of Crohn's & colitis.
[169] D. Sheppard,et al. The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP–dependent activation of TGF-β1 , 2002, The Journal of cell biology.
[170] W. Davis,et al. Crohn's disease and Mycobacterium avium subsp. paratuberculosis: the need for a study is long overdue. , 2012, Veterinary immunology and immunopathology.
[171] K. Kolho,et al. Serum MMPs 7–9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease , 2012, Scandinavian journal of gastroenterology.
[172] D. Graham,et al. Review article: Mycobacterium avium subsp. paratuberculosis as one cause of Crohn's disease. , 2001, Alimentary pharmacology & therapeutics.
[173] H. Verspaget,et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[174] C. Hiruma-Lima,et al. Suppression of TNBS-induced colitis in rats by 4-methylesculetin, a natural coumarin: comparison with prednisolone and sulphasalazine. , 2012, Chemico-biological interactions.
[175] M. Sans,et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. , 2009, Gastroenterology.
[176] M. Rojas,et al. Selective Ablation of Matrix Metalloproteinase-2 Exacerbates Experimental Colitis: Contrasting Role of Gelatinases in the Pathogenesis of Colitis1 , 2006, The Journal of Immunology.
[177] M. Grisham,et al. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. , 2007, American journal of physiology. Gastrointestinal and liver physiology.
[178] K. Hahm,et al. Novel Application of Proton Pump Inhibitor for the Prevention of Colitis-Induced Colorectal Carcinogenesis beyond Acid Suppression , 2010, Cancer Prevention Research.
[179] V. Binder,et al. Familial occurrence and inheritance studies in inflammatory bowel disease. , 1996, The Netherlands journal of medicine.
[180] S. Targan,et al. A genome-wide search identifies potential new susceptibility loci for Crohn's disease. , 1999, Inflammatory bowel diseases.
[181] R. Xavier,et al. Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.
[182] P. Hunter,et al. Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid‐based techniques: A systematic review and meta‐analysis , 2008, Inflammatory bowel diseases.
[183] C. V. van Noorden,et al. The role of gelatinases in colorectal cancer progression and metastasis. , 2004, Biochimica et biophysica acta.
[184] M. Keeffe. Digestive diseases and sciences , 2005, Digestive Diseases and Sciences.
[185] V. Yang,et al. Notch1 regulates the effects of matrix metalloproteinase-9 on colitis-associated cancer in mice. , 2011, Gastroenterology.
[186] A. Gasbarrini,et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. , 2006, Gastroenterology.
[187] H. Emonard,et al. Involvement of Fibronectin Type II Repeats in the Efficient Inhibition of Gelatinases A and B by Long-chain Unsaturated Fatty Acids* , 2001, The Journal of Biological Chemistry.
[188] P. Treuting,et al. Serum biomarkers in a mouse model of bacterial‐induced inflammatory bowel disease , 2008, Inflammatory bowel diseases.
[189] F. Guarner,et al. Transforming growth factor‐beta type 1 receptor (ALK5) and Smad proteins mediate TIMP‐1 and collagen synthesis in experimental intestinal fibrosis , 2011, The Journal of pathology.
[190] Hiroyuki Yamamoto,et al. The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis , 2003, Journal of Gastroenterology.
[191] K. Jordan,et al. A commentary on current perspectives on Mycobacterium avium subsp. paratuberculosis, Johne’s disease and Crohn’s disease: A review by Over et al. (2011) , 2012, Critical reviews in microbiology.
[192] A. Murakami,et al. Auraptene Decreases the Activity of Matrix Metalloproteinases in Dextran Sulfate Sodium-Induced Ulcerative Colitis in ICR Mice , 2006, Bioscience, biotechnology, and biochemistry.
[193] L. Matrisian,et al. Matrilysin (matrix metalloproteinase‐7) expression in ulcerative colitis–related tumorigenesis † , 2002, Molecular carcinogenesis.
[194] P. Garg,et al. Constitutive expression of MMP9 in intestinal epithelium worsens murine acute colitis and is associated with increased levels of proinflammatory cytokine Kc. , 2013, American journal of physiology. Gastrointestinal and liver physiology.
[195] B. Molnár,et al. Peripheral Blood Based Discrimination of Ulcerative Colitis and Crohn’s Disease from Non-IBD Colitis by Genome-Wide Gene Expression Profiling , 2011, Disease markers.
[196] O. Inatomi,et al. Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts , 2007, Journal of Gastroenterology.
[197] Yingde Wang,et al. Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis. , 2006, World journal of gastroenterology.
[198] K. Imai,et al. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium , 2006, The Journal of pathology.
[199] B. Sandhu,et al. Epidemiology of inflammatory bowel diseases in childhood , 2006, Indian journal of pediatrics.
[200] G. Batist,et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[201] A. Di Sabatino,et al. Matrix metalloproteinase‐3 production by gut IgG plasma cells in chronic inflammatory bowel disease , 2008, Inflammatory bowel diseases.
[202] S. Szabó,et al. Role of anti-angiogenic factor endostatin in the pathogenesis of experimental ulcerative colitis. , 2011, Life sciences.
[203] C. Elson,et al. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota , 2005, Immunological reviews.
[204] G. J. Rosa,et al. Evidence for a Novel Gene Expression Program in Peripheral Blood Mononuclear Cells from Mycobacterium avium subsp. paratuberculosis-Infected Cattle , 2003, Infection and Immunity.
[205] Thomas Lengauer,et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1 , 2007, Nature Genetics.
[206] A. Henschen-Edman,et al. Structural Determinants of Procryptdin Recognition and Cleavage by Matrix Metalloproteinase-7* , 2003, The Journal of Biological Chemistry.
[207] M. Pakarinen,et al. Matrix metalloproteinases in the restorative proctocolectomy pouch of pediatric ulcerative colitis. , 2012, World journal of gastroenterology.
[208] G. Corazza,et al. Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab , 2009, European journal of gastroenterology & hepatology.
[209] D. Sauder,et al. Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. , 2002, Journal of the American Academy of Dermatology.